Full-year 2024 revenue increased by 32.9% to $27.0 million from $20.4 million revenue in 2023.Revenue growth driven by B2B2C channel including employers and health plans resulting in recurring revenues which increased by 300% year over year as core business continues to gain traction.Completed $25.6 million equity financing, resulting in a $34.5 million proforma cash balance as of year-end; proforma balance expected to fund operations through operational cash flow breakeven run rate by the end of 2025 with a larger cushion.Revenue growth and efficient post-merger integration resulted in a decrease in operating loss in the quarter ended December 31, 2024, of 35% to $11.7 million on a GAAP bas

Company to host conference call and webcast at 8:30am Eastern Time NEW YORK, March 4, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 4th quarter ended December 31st, 2024 and will host a conference call and webcast at 8:30 am Eastern Time, on Monday, March 10th, 2025, before the market opens. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call. Conference Call Details Date: Monday, March 10th, 2025, 8:30am ET Dial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international) Call me™: ht

Significant participation from existing shareholders and accredited healthcare investors, which the company believes underscores confidence in its strategyFinancing supports execution of long-term growth initiatives focused on high-margin, scalable recurring revenues across B2B (Business-to-Business) and pharma channelsNEW YORK, Jan. 21, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a prominent leader in the global digital health industry, announced today the successful closing of a $25.6 million private placement of convertible preferred stock, priced in accordance with Nasdaq market rules. The majority of the funds were secured from existing shareholders,

Demonstrated strong improvements in financial performance and business momentum.Q3 revenue of $7.42 million increased 18.7% over Q2 2024 and 111% compared to Q3 2023, driven by expansion of B2B2C revenues.Q3 operating loss decreased sequentially by 25.7% to $12 million on a GAAP basis and by 33.3% to $7.1 million on a non-GAAP basis over Q2 2024.Executed synergies from the Dario-Twill merger, expected to reduce operating expenses by approximately 38% by Q1 2025 (compared to Q1 2024) and contributing to an expected 49% reduction in operating losses by Q1 2025 and 59% in non-GAAP operating losses.Significant wins include: 10 B2B2C clients, including a national Medicare advantage health plan, a

Company to host conference call and webcast at 8:30am ET NEW YORK, Oct. 23, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a global leader in digital health, announced today that it will release its financial results for the 3rd quarter ended September 30th, 2024 and will host a conference call and webcast at 8:30 am Eastern Time, on Thursday, November 7th, 2024, before the market opens.     Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call. Conference Call Details Date: Thursday, November 7th, 8:30am ET Dial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international) Call me™: https://emportal

Q2 revenue of $6.26 million reflects an increase of 8.6% over Q1 2024, and an increase of 1.7% over Q2 of 2023, driven primarily by increased B2B2C revenues Q2 commercial and consumer revenues totaled $7.34 million before a non-recurring price concession in collaboration with a pharma partner, compared to $3.57 million for Q2 of 2023, representing a 105% increaseCore B2B2C revenue channel, recurring revenues from employers and health plans in the second quarter totaled $5.5 million, an increase of 315% year over year and 60% sequentially from the first quarter of 2024Made progress on collaboration with existing and potential pharma clients to accelerate a transformation to a new, recurring,

Company to host conference call and webcast at 8:30am ET NEW YORK, July 30, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it will release its financial results for the 2nd quarter ended June 30th, 2024, on Thursday, August 8th, 2024, before the market opens and will host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer, and Steven Nelson, Chief Commercial Officer, will host the call. Conference Call Details Date: Thursday, August 8th, 8:30am ET Dial-in Number: 1-800-717-1738 (domestic) or 1-646-307-1865 (international) Call me™: https://emportal.ink/3V5ogDP Part

First quarter revenue of $5.8 million reflects an increase of 59% over fourth quarter of 2023 primarily resulting from an increase in B2B2C revenues and reflects a decrease of 18.5% compared to the first quarter of 2023 due to milestone driven revenues.Core revenue channel B2B2C, employers and health plans recurring revenues in the first quarter totaled $3.47 million, an increase of 176% year over year and 210% sequentially from $1.12 million in the fourth quarter 2023 as the core business continues to gain traction, as well as the addition of Twill Inc. revenues post February 15th closingLaunched the Aetna platform generating revenue in Q1 2024 as Aetna continues to add employers to the pla

Company to host conference call and webcast at 8:30am ET NEW YORK, May 7, 2024 /PRNewswire/ --  DarioHealth Corp. (NASDAQ:DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it will release its financial results for the 1st quarter ended March 31st, 2024, on Wednesday, May 15th, 2024, before the market opens and will host a conference call and webcast at 8:30 am Eastern Time. Erez Raphael, Chief Executive Officer and Rick Anderson, President, will host the call. Conference Call Details Date: Wednesday, May 15th, 8:30am ET Dial-in Number: 1-888-886-7786 (domestic) or 1-416-764-8658 (international) Call me™: https://emportal.ink/3VOj7AC Participants can use t

Full-year 2023 revenue of $20.4 million reflects a decrease from 2022 revenue of $7.3 due to a managed decrease in B2C and strategic milestone revenue as the core B2B2C revenue increased.2023 B2B2C, employers and health plans recurring revenues increased 39% year over year as the core business continues to gain traction.Commercial revenues in 2023 generated majority of the revenue with B2B2C growing from 13% to 25% of total revenue from 2022 to 2023.GAAP operating expenses decreased by 11.2% sequentially from the third quarter of 2023.Non-GAAP operating expenses decreased 9.4% sequentially from the third quarter to $9.9M. Signed multiple customers onto the Aetna platform which subsequently l

4 - DarioHealth Corp. (0001533998) (Issuer)

4 - DarioHealth Corp. (0001533998) (Issuer)

4 - DarioHealth Corp. (0001533998) (Issuer)

4 - DarioHealth Corp. (0001533998) (Issuer)

4 - DarioHealth Corp. (0001533998) (Issuer)

4 - DarioHealth Corp. (0001533998) (Issuer)

4 - DarioHealth Corp. (0001533998) (Issuer)

4 - DarioHealth Corp. (0001533998) (Issuer)

Healthcare innovator and former Accenture executive brings deep industry relationships to advance Dario's AI-driven chronic care platform. NEW YORK, Feb. 27, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in AI-driven digital health solutions, today announced the appointment of Lawrence (Larry) B. Leisure to its Board of Directors, bringing four decades of healthcare leadership, managed care expertise, and digital health innovation to the company's governance. Mr. Leisure's extensive experience working with health plans, health systems, consultants, and employer coalitions, combined with his deep understanding of health policy, reimbursement, and va

Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. "OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors," sa

After two decades of successfully scaling multiple healthcare companies, Steven Nelson joins DarioHealth as Chief Commercial Officer to accelerate revenue growth across the health plans, employers and pharma channels NEW YORK, June 5, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario", "DarioHealth" or the "Company"), a leader in the global digital health market, announced today a strategic reorganization designed to streamline leadership and focus the organization on accelerating its commercialization efforts. This move reflects the Company's commitment to bringing its innovative solutions to the market faster, maximizing customer impact, and driving the organization to profitabi

Dario also appoints digital veteran, Arnaud Robert, to the role of Strategic Advisor to the Chief Executive Officer The appointments strengthen Dario's ability to scale its digital therapeutics platform to meet growing market demand  NEW YORK, April 4, 2023 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company" or "Dario"), a leader in the global digital therapeutics (DTx) market, announced today that digital health veteran, Eitan Shay, is joining the Company in the newly created position of Chief Product Officer. Mr. Shay previously held product leadership roles at digital health companies Livongo and Teladoc Health as well as senior leadership roles at Meta Platforms.  Dario also

Mr. Kaplan brings a wealth of experience in business strategy specifically in healthcare and digital health NEW YORK, Feb. 23, 2023 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today the appointment of Jon Kaplan to serve as a board member effective immediately. Mr. Kaplan is a Managing Director and Senior Partner at Boston Consulting Group (BCG), serving as a core member of the strategy and health care practices and leading BCG's transformation initiative for the future evolution of healthcare in the United States and its impact globally. He has previously served in advisory board roles at digital health

NEW YORK, Nov. 15, 2021 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO), a pioneer in the global digital therapeutics market, today announced that the Company appointed Jerrod Helms to the newly created role of Chief Commercial Officer (CCO) to support the rapid expansion of business in the employer, payer, provider and partnership markets that the company has seen over the last quarter and the anticipated acceleration into 2022. Mr. Helms will report to Rick Anderson, President and General Manager North America. "Dario is experiencing significant commercial acceleration as demonstrated by the number of recent customer wins and the expanding opportunity going forward as demand for our multi-

NEW YORK, Jan. 21, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today the appointment of Chris Chan as Senior Vice President of Employer Sales. Mr. Chan will be responsible for leading growth initiatives in the self-insured employer market. Mr. Chan brings a unique perspective and strong understanding of the self-insured employer marketplace for digital health and DTx solutions. Mr. Chan was most recently Chief Marketing Officer at SleepQuest; a sleep apnea focused technology and telehealth company. Prior to that role, Mr. Chan was a founding member, team leader, and innovation imaginer at Mercer LABS, where he

NEW YORK, January 7, 2021 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced today the appointment of Claudia Rimerman Kraut as Vice President of Broker and Consultant Partnerships. In the newly created role, Ms. Kraut will be a senior member of the employer sales team and lead Dario's benefit consultant and alliance outreach as part of the self-insured employers and managed care sales organization. Ms. Kraut brings a strong combination of benefits, partnerships, and digital health experience, most recently as Director of Alliances at Omada Health, where she successfully grew alliances with benefits consultants and other partne